New PAH drug shows promise in Mid-Stage trial
Disease control
Completed
This study tested an investigational drug called KER-012 in 113 adults with pulmonary arterial hypertension (PAH), a serious lung condition that makes it hard to breathe. Participants took KER-012 or a placebo alongside their usual PAH medications. The goal was to see if KER-012 …
Phase: PHASE2 • Sponsor: Keros Therapeutics, Inc. • Aim: Disease control
Last updated May 26, 2026 12:02 UTC